Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA Chuang, J. C., Liang, Y., Wakelee, H. A. 2017; 31 (1): 31-?


The use of 4 cycles of cisplatin-based adjuvant chemotherapy is now the standard of care for patients with resected stage II and IIIA non-small cell lung cancer. Neoadjuvant chemotherapy lacks the same level of data as adjuvant treatment, but meta-analyses of this approach support its use. Selection of patients who are most likely to benefit from chemotherapy remain elusive. Ongoing adjuvant trials are exploring biomarkers, molecularly targeted agents, postoperative radiation therapy, and immunotherapy.

View details for DOI 10.1016/j.hoc.2016.08.011

View details for Web of Science ID 000390984800004

View details for PubMedID 27912832